The use of medical management of ectopic pregnancy has become an accepted alternative to surgical therapy. Methotrexate, a folic acid antagonist, is the most widely studied agent. The most commonly used protocol consists of methotrexate 50 mg/m 2 of actual body weight. Assessment of human chorionic gonadotropin (hCG) levels is repeated on days 4 and 7. Repeat methotrexate dosing is performed for hCG drops <15%. Contraindications include hemodynamically unstable patients or those with elevated liver enzymes, low white blood count, or abnormal renal function. hCG levels are most predictive of success. A success rate of above 90% is achievable.
Introduction
Before the development of surgical treatment options, mortality for presumed ectopic pregnancy was reported to be 67%. 1 In 1884, Tait reported a series of 5 patients treated with salpingectomy and subsequently reported a mortality of only 5%. 2 Although refinements in surgical techniques, anesthesia, blood banking, and early diagnosis continued to decrease the mortality rate, surgery remained the only viable treatment option for ectopic pregnancy for the next century.
Methotrexate is a folic acid analog that has been used extensively in medicine for the treatment of certain neoplastic diseases, severe psoriasis, and adult rheumatoid arthritis. Methotrexate competitively binds to the enzyme dihydrofolic acid reductase, an enzyme that converts dihydrofolate to tetrahydrofolate. This binding prevents the reduction of folate to its active form, tetrahydrofolate. Tetrahydrofolate serves to transport 1-carbon groups during the synthesis of purine nucleotides and thymidylate. Without tetrahydrofolate, DNA synthesis and repair and cellular replication are impaired. Actively proliferating cells such as malignant cells, bone marrow cells, fetal cells, and mucosal cells of the mouth, intestine, and urinary bladder are generally the most sensitive to the effects of methotrexate. Methotrexate is rapidly cleared from the body by the kidneys, with 90% of an intravenous dose excreted unchanged within 24 hours of injection. 3 Before its use for treatment of ectopic pregnancy, methotrexate was used in gynecology only for the treatment of gestational trophoblastic disease. In 1982, Tanaka and colleagues reported treatment of an interstitial ectopic pregnancy in a patient with a 15-day course of intramuscular methotrexate. This was the first report of methotrexate being used in the treatment of an ectopic pregnancy. 4 Since then, methotrexate therapy has not only become a widely accepted therapy for treatment of ectopic pregnancy but is often considered first-line therapy.
The initial methotrexate medical protocols required prolonged hospitalization, and the multiple doses of methotrexate were associated with significant side effects. Since these early protocols, refinements have allowed outpatient therapy, frequently requiring only 1 dose of methotrexate, and are associated with fewer side effects. Protocols using other agents such as potassium chloride, hyperosmolar glucose, dactinomycin, prostaglandins, and RU 486 for the medical management of ectopic pregnancy have also been developed. These agents may be given by direct injection into the ectopic sac, or, in the case of dactinomycin, prostaglandins, and RU 486, given systemically by oral, intramuscular, or intravenous routes. However, due to the limited experience with these agents, their use must still be considered experimental until further data are available.
Initially, all the methotrexate protocols used in the treatment of ectopic pregnancy required multiple doses of methotrexate alternating with reduced folinic acid (citrovorum rescue factor). These protocols generally were characterized with prolonged hospital stays, lengthy courses of treatment, and higher-than-acceptable toxicity rates. Side effects encountered included changes in liver functions, bone marrow suppression, nausea, and stomatitis. Considering these side effects and patient costs, this form of treatment, although perhaps superior to surgical therapy, was not ideal.
In 1989, Stovall et al 5 at the University of Tennessee, Memphis, TN, demonstrated that medical management of ectopic pregnancies with methotrexate could be performed safely on an outpatient basis. In their protocol, intramuscular methotrexate, 1 mg/kg of actual body weight, was given on alternating days with citrovorum rescue factor 0.1 mg/kg (Table 1) 
Single-dose Methotrexate Protocol
As the majority of patients treated in the previously quoted multidose methotrexate study had falling hCG levels before the expected peak effect of the second and third injection, it was theorized that many of these patients would have been successfully treated with only a single dose of methotrexate. Subsequently, a protocol using only single-dose methotrexate without the use of citrovorum rescue factor was developed at the University of Tennessee, Memphis, TN. 6 This protocol is detailed in Table 2 . Because the majority of patients received only 1 dose of methotrexate, this protocol is commonly referred to as ''single-dose methotrexate.'' Compared with previous multidose methotrexate protocols, single-dose methotrexate is less expensive, has fewer side effects, requires less intensive patient monitoring, and has greater patient acceptance. Over 700 patients at the University of Tennessee Medical Management of Ectopic Pregnancy 425 to date have been treated with this protocol, with a success rate of approximately 90%. A detailed analysis of success rates of various subgroups from the first 315 patients from this database has been published and is shown in Table 3 . 7 This success rate is particularly noteworthy as there was no upper limit placed on hCG levels, and the limits on the size of an ectopic gestation that could be treated were liberalized several times as experience with the protocol increased. For the purposes of this particular protocol, size was defined as that including only the gestational sac if it could be delineated from the surrounding hematoma. If a gestational sac could not be distinguished, the size of the entire mass was used. Currently, the upper limit of ectopic size for medical therapy in all published data from the University of Tennessee is 4 cm if cardiac activity is not present and 3.5 cm if cardiac activity is present. However many variations of this protocol used elsewhere still limit the ectopic pregnancy size to 3 cm or less to be eligible for medical therapy. Interestingly, the upper limit on ectopic size in the original methotrexate protocols was completely empiric, and some information suggests that ectopic size may not be a significant risk factor for failure. 8 As with any medical therapy, patients should be counseled about the risk and benefits of treatment, the expected course and duration of treatment, and the importance of follow-up before beginning a methotrexate treatment protocol. Traditionally, all patients were screened with a baseline hCG, Rhesus (Rh) factor, complete blood count, aspartate aminotransferase (AST), creatinine, and blood urea nitrogen. White cell counts <1500, abnormal renal function, or elevation in the liver function values more than twice the upper limit of normal are generally considered contraindications to methotrexate. In the absence of a history of renal disease, previous hepatitis, liver dysfunction, or evidence of a depressed immune system, it 426 Lipscomb is exceedingly rare to find patients with a laboratory finding that would be a contraindication to methotrexate. Therefore, many current protocols do not include a screening for complete blood count, AST, creatinine, or blood urea nitrogen before initial methotrexate dosing. However, these tests should be performed before a second dose of methotrexate even if results are initially normal. The presence of fluid in the pelvis on ultrasound, presumably blood, is considered by many to be a contraindication to medical therapy because of fears that this may indicate ongoing tubal rupture. In the older literature, approximately 70% to 83% of all ectopic pregnancies had nonclotting blood in the pelvis when a culdocentesis was performed. 9, 10 Interestingly, 50% to 62% of the patients with positive culdocentesis in these studies were found to have an unruptured fallopian tube. This blood may also produce mild peritoneal signs (ie, rebound) on abdominal examination. On the basis of these data, fluid confined to the pelvis and rebound in an otherwise hemodynamically stable patient was not considered a reason for surgical intervention in the protocol used at the University of Tennessee. Although there are no data to indicate that increasing amount of blood in the pelvis is associated with increasing failure rates with methotrexate, 8 we empirically consider blood in the upper abdomen a strong relative contraindication to medical therapy. Hemodynamically stable patients with smaller amount of blood confined to the pelvis are routinely treated medically at our institution. If there is concern that this blood is the result of active bleeding, hospitalization with observation and serial hematocrits is indicated.
The day methotrexate is given is considered day 1. Assessment of hCG is repeated on days 4 and 7. If the hCG level declines <15% between days 4 and 7, a second dose of methotrexate is given and the protocol restarted at a new day 1. A repeat blood count and AST levels are obtained before retreatment. We routinely obtain these laboratory tests with the hCG level on all day 7 patients to prevent delays if retreatment is needed. If the hCG level declines Z15%, hCG titers are then followed weekly until titers reach <15 mIU/ mL. Although we have never had a complication using this endpoint, many physicians choose to follow hCG titers to negative, generally 3 to 5 mIU/mL depending on the assay used. If the hCG level declines <15% in any week, repeat methotrexate dosing is performed and the protocol is again restarted at a new day 1. Although this protocol is referred to as single-dose methotrexate, approximately 20% of patients will require >1 treatment cycle. 7 In the University of Tennessee's experience, the mean time to resolution in successfully treated patients is approximately 35 days. However, resolution may take as long as 109 days. Tubal rupture may also be delayed, with the longest time from initial treatment to rupture in our database occurring at 31 days. 7 Because of the inconvenience and cost to the patient of obtaining multiple hCG levels, alternative monitoring protocols have been developed to eliminate obtaining hCG levels at day 4. [11] [12] [13] These protocols have used a decline of 25% to 50% between days 1 and 7 to determine the need for a repeat dose of methotrexate. Until recently, most of these protocols were empiric, and little if any published data on sensitivity and specificity were available to support the recommendations. A recent review retrospectively analyzed the use of a 50% cutoff between days 1 and 7. 11 All those who would have required a second dose of methotrexate with a 15% decline between days 4 and 7 were identified. However, over 40% of patients would have required a second dose with >2 patients receiving a second dose of methotrexate to avoid obtaining hCG levels at day 4.
Ultrasound is generally not repeated for patients except to evaluate severe During treatment, patients are required to avoid alcohol and folate-containing vitamins. Sexual intercourse or pelvic examinations could potentially rupture the tubal hematoma commonly noted on ultrasound after methotrexate treatment and therefore should be avoided. Patients are also requested to avoid cabbage, onions, leeks, and other potential gas producing foods to avoid the gastrointestinal distress from excess intestinal gas production, which appears to be common after methotrexate treatment. Patients are instructed to use over-the-counter simethicone-containing antigas agents as needed for this problem.
Single Versus Multidose Methotrexate
The most appropriate methotrexate treatment protocol remains controversial. With experience, various institutions have developed multiple variations of the original protocol. These protocols differ in dose, dosing regimen, route of administration, and follow-up options. Another section within this article will address the more common protocol options and their variations in detail. However, a brief comment on 2 most commonly used treatment protocols in the United States seems appropriate here. These 2 protocols are the original multidose protocol and the so called ''single-dose'' protocol.
A well performed meta-analysis of ''single-dose'' and ''multidose'' methotrexate protocols showed ''multidose'' to be significantly superior to ''single-dose'' methotrexate with success rates of 241/260 (92.7%) versus 940/1067 (88.1%); P = 0.035. 15 This analysis was heavily weighted by patients from the University of Tennessee database with 100 of the multidose patients (including 4 patients treated for persistent trophoblastic disease after surgery who were excluded in this study) and 350 of the single-dose patients involved in the meta-analysis. Due to the inherent weaknesses of meta-analysis, compiled data rather than individual raw data must be compared, making it impossible to directly compare patients.
However, a direct comparison of the single and multidose patients from the University of Tennessee showed no significant difference in success rates between multidose [92/97 (95%)] and single-dose protocols [492/546 (90%); P = 0.18]. 16 Both groups were comparable with regard to factors generally thought to increase failure except for the presence of ectopic cardiac activity, which was more common in the single-dose group. These factors would be expected to bias the study against the singledose protocol.
Interestingly, the cure and failure rates are quite similar in both studies. It is possible that failure to find statistical significance in the latter study may have been because of its smaller sample size rather than a true lack of significance. There is 1 small prospective comparison of singledose versus multidose methotrexate involving 108 patients who showed no statistical difference between the 2 groups. 17 The failure rates of 92.6% for multidose and 88.9% for single-dose methotrexate were also quite similar to both previously cited studies. Unfortunately, because of its relatively small size the study does not have the statistical power to prove there is no true difference.
Given the greater simplicity and low complication rate of single-dose methotrexate, the single-dose methotrexate protocol would seem to have an advantage over the multidose protocol if the success rates are indeed similar. Even if the approximately 4% difference in failure rates are true, the increased success rates may not offset the other disadvantages associated with multidose methotrexate protocols.
Predictors of Success for Single-dose Methotrexate
Since the development of methotrexate treatment for tubal ectopic pregnancies, many clinical variables have been suggested as prognostic of success with methotrexate therapy for ectopic pregnancy. The most commonly quoted predictors of success are hCG levels, progesterone levels, ectopic size, the presence of ectopic cardiac activity, and the presence of free peritoneal blood. Unfortunately, there is no consensus on which selection criteria are reliable. Because of the small numbers of treated patients previously available for analysis, it has been difficult to determine the true effect of these parameters on success rates. However, in the largest review to date, the effect of ectopic size, mass volume, initial serum hCG levels, initial serum progesterone levels, and the presence or absence of ectopic fetal cardiac activity or free peritoneal blood were evaluated with respect to their effect on success with single-dose methotrexate treatment of 350 consecutive tubal ectopic pregnancies. 8 Preliminary univariate analysis showed only initial hCG and progesterone levels and the presence of ectopic cardiac activity to be statistically significant. Interestingly, ectopic size, hematoma volume, or the presence of free peritoneal blood confined to the pelvis were not significant risk factors for treatment failure. Logistic regression on these 3 statistically significant variables showed hCG to be the only significant contributing factor to the failure rate with a marked increase in the failure rate seen after 15,000 mIU/mL. This would seem to indicate that many previous relative contraindications for medical therapy are invalid, with only hCG being predictive. Failure rates by hCG levels are based on this study presented in Table 4 . As can be noted in this table, the failure rates increase almost linearly. Physicians can use these failure rates to determine at what levels they will be comfortable medically treating ectopic pregnancies and to counsel patients on the relative chance of success with single-dose methotrexate.
Additional publications have suggested that a history of ectopic pregnancy may also be an independent risk factor for failure of methotrexate therapy. This appears to be unrelated to the method of treatment for the prior ectopic pregnancy. 18 
Complications of Methotrexate Therapy

SEPARATION PAIN
It is common for patients to experience an episode of increased abdominal pain during medical treatment for an ectopic pregnancy. Although the true cause of this pain is unknown, it is likely that the pain results from either tubal abortion or tubal stretching from hematoma formation. Fortunately the pain is generally self-limiting and controlled with nonsteroidal anti-inflammatory agents such as ibuprofen, 800 mg by mouth. Interestingly, nonsteroids appear to be more effective for this type of pain compared with many narcoticcontaining oral analgesics. Although
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nonsteroidal anti-inflammatory agents are known to interfere with the excretion of methotrexate, their use appears to be well tolerated in ectopic patients. This is likely due to the relative low dose of methotrexate used in the medical protocols and lack of a continuous infusion. This appears to be somewhat comparable with the use of nonsteroids with chronic low-dose methotrexate in the treatment of rheumatoid arthritis. The prescription of narcotic oral medications for use at home should be avoided to avoid masking a true tubal rupture. At our institution, patients are advised to take ibuprofen for any increase in pain and to rest for 1 hour. If significant relief does not occur, they are instructed to return to the office or hospital for evaluation. The prescription of narcotic oral medications for use at home should be avoided to avoid masking a true tubal rupture. Hemodynamically stable patients with severe pain can be admitted and observed with serial hematocrits. An ultrasound can also be obtained to document the absence of blood outside the pelvis, indicating probable tubal rupture. As noted previously, the presence of presumed blood confined to the pelvis is not an indication alone for surgical intervention in our protocols.
In an earlier review of our first 258 ectopic pregnancies treated with singledose methotrexate, 34 patients required hospitalization for severe unrelieved pain and 22 other patients were evaluated as outpatients and released. 19 Twenty-seven of these 34 hospitalized patients (79%) did not require surgery during this hospitalization. Two hospitalized patients and 1 outpatient ultimately underwent surgery at a time remote from evaluation. Two of these surgeries were in patients who refused further medical therapy and requested surgery.
In many centers, patients with separation pain requiring evaluation undergo surgical therapy. Extrapolating from the above data, our success rate would have dropped to 82.5% if those patients hospitalized for separation pain underwent surgery and 74% if all patients with pain severe enough to require evaluation underwent surgery. We believe early surgical intervention in patients experiencing separation pain may be 1 reason for the lower success rate reported with single-dose methotrexate therapy by other institutions.
HEMATOMA FORMATION
After treatment with methotrexate, 56% of ectopic masses will increase in size if followed by ultrasound. 14 We have observed hematomas 7 to 8 cm in size develop after treatment with methotrexate. Interestingly, most of these patients are asymptomatic. These masses will frequently persist for some time, with the longest documented time to resolution being 108 days. 14 Persistence after the disappearance of hCG is also common. These masses should not be interpreted as a treatment failure, as they probably represent resolving hematomas rather than trophoblastic tissue.
SIDE EFFECTS
Potentially serious side effects, including marrow suppression, pulmonary fibrosis, nonspecific pneumonitis, liver cirrhosis, renal failure, and gastric ulceration, can occur with methotrexate. However, these are invariably seen when methotrexate is given in high doses with frequent dosing intervals, that is, chemotherapeutic protocols for malignancy. Such side effects are rarely seen with the doses, dosing intervals, or treatment duration used for medical management of ectopic pregnancy. None of the approximately 800 patients treated at our institution have experienced serious side effects. The most common side effect observed with the single-dose methotrexate protocol is excessive flatulence and bloating due to intestinal gas formation. This problem is usually self-limited and handled as previously described. Transient mild elevation of results of liver-function tests can be noticed but rarely exceed twice the upper limit of normal. These tests invariably return to normal within 2 weeks. Stomatitis may also be seen in patients receiving >1 methotrexate injection and is generally also self-limited. If needed, viscous lidocaine can be used for symptomatic relief.
Summary
Medical therapy for treatment of ectopic pregnancy has become a commonly used alternative to surgical therapy. Multiple protocols with variations in methotrexate dose, dosing interval, and follow-up have been published that allow for individualization on the basis of the resources available, comfort level of the physician, and desires of the patient. It is hoped that this article will aid the physician in making some of these decisions.
